Effects of aspirin for primary prevention of cardiovascular diseases in type 2 diabetes mellitus patients at Bangmulnak hospital, Phichit province.
Article Sidebar
Main Article Content
Abstract
Background and Objectives: The benefit and safety of prescribing aspirin as primary prevention of cardiovascular diseases are still unclear. This research studied about effects of aspirin for primary prevention of cardiovascular diseases compare with non-aspirin use in type 2 diabetes mellitus patients and side effects.
Design: Therapeutic observational retrospective cohort research
Materials and Methods: The data of type 2 diabetes patients that aged 40 years or older without established cardiovascular diseases were collected from medical record database from January 1st, 2014 to December 31st, 2018. Patients were categorized to aspirin and non-aspirin group. Primary outcome was the first cardiovascular event. Safety outcome was the first major bleeding event. All outcomes were followed until December 31st, 2021.
Results: A total of 682 patients were recruited in this study. During a median follow-up period was 4.9 years, incidence of the first cardiovascular event between aspirin and non-aspirin group were not significant differences (adjusted hazard ratio, 0.93; 95% confidence interval (CI), 0.51-1.71; adjusted p-value=0.816). The effects in subgroup analyses were still in the same pattern. The major bleeding events increased in aspirin group especially gastrointestinal bleeding (adjusted Hazard Ratio, 3.50; 95% CI, 1.47-8.34; adjusted p-value=0.005).
Conclusions: The aspirin use in type 2 diabetes mellitus patients did not have effect on primary prevention of cardiovascular diseases but increased risk of gastrointestinal bleeding.
Keywords: aspirin, diabetes mellitus, primary prevention, cardiovascular disease
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The content and information in articles published in the PCFM journal are solely the opinions and responsibilities of the authors. The journal's editorial board does not necessarily agree with or share any responsibility for them.
All articles, information, content, images, etc., published in the PCFM journal are the copyright of the PCFM journal. If any individual or organization wishes to reproduce, distribute, or use any part or the entirety of the content, they must obtain written permission from the PCFM journal beforehand.
References
Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60.
Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22.
Association AD. Standards of Medical Care in Diabetes-2010. Diabetes Care. 2010;33(Supplement_1): S11-S61.
สมาคมโรคเบาหวานแห่งประเทศไทย, สมาคมต่อมไร้ท่อแห่งประเทศไทย, กรมการแพทย์, สำนักงานหลักประกันสุขภาพแห่งชาติ. แนวทางการป้องกันและรักษาภาวะแทรกซ้อนของหลอดเลือดหัวใจและหลอดเลือดสมอง. แนวทางเวชปฏิบัติสำหรับโรคเบาหวาน 2557. กรุงเทพมหานคร: ศรีเมืองการพิมพ์; 2557. หน้า 73-8.
Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-39.
Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-46.
McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018; 379:1519-28.
Pawich Paktipat PP, Suratchada Chanasopon, Sirin Bhongchirawattana, Rattayaporn Jaikusol, Penporn Pararat. 5-years Follow-up after primary prevention of cardiovascular events with aspirin in patients with type ii diabetes mellitus. Thai Journal of Pharmacy Practice. 2019;12:151-62.
Wannakon Chuemongkon KB, Kamonwan Tumpoo. Aspirin use for the primary prevention of cardiovascular diseases in type 2 diabetic patients. Srinagarind Medical Journal 2019;34:184-9.
Sritara P, Tatsanavivat P, Tulyadachanon S, Sangwatanaroj S, Yamwong S, Vathesatogkit P. Thai CV risk score [Internet]. 2015 [cited 2023 Oct 1]. Available from: https://med.mahidol.ac.th/cardio_vascular_risk/thai_cv_risk_score/
Saito Y, Okada S, Ogawa H, Soejima H, Sakuma M, Nakayama M, et al. Low-dose aspirin for primary prevention of cardiovascular events in patients with type 2 diabetes mellitus: 10-year follow-up of a randomized controlled trial. Circulation. 2017; 135:659-70.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-209.
Bibbins-Domingo K; U.S. Preventive services task force. aspirin use for the primary prevention of cardiovascular disease and colorectal cancer: u.s. preventive services task force recommendation statement. Ann Intern Med. 2016;164:836-45.
Langsted A, Nordestgaard BG. Smoking is associated with increased risk of major bleeding: a prospective cohort study. Thromb Haemost. 2019;119:39-47.
Mahmoud AN, Gad MM, Elgendy AY, Elgendy IY, Bavry AA. Efficacy and safety of aspirin for primary prevention of cardiovascular events: a meta-analysis and trial sequential analysis of randomized controlled trials. Eur Heart J. 2019;40:607-17.
Guirguis-Blake JM, Evans CV, Perdue LA, Bean SI, Senger CA. Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the us preventive services task force. JAMA. 2022;327:1585-97.
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet. 1998;351(9098):233-41.
Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62.
Marquis-Gravel G, Roe MT, Harrington RA, Muñoz D, Hernandez AF, Jones WS. Revisiting the role of aspirin for the primary prevention of cardiovascular disease. Circulation. 2019;140:1115-24.
Berger JS. Aspirin for Primary prevention-time to rethink our approach. JAMA Netw Open. 2022;5: e2210144. PubMed PMID: 35471577
